Background: Excessive amounts of bile acids entering the colon due to bile acid
| INTRODUCTION
Bile acids are necessary for normal absorption of lipids in the small intestine. They are produced in the liver, then excreted with the bile to the small intestine and reabsorbed in the terminal ileum to reach the liver by the portal vein. If excessive amounts of bile acids reach the colon, increased colon electrolyte and water secretion, and enhanced motility may cause diarrhoea.
1,2 Thus, up to 45% of patients considered as having irritable bowel syndrome with diarrhoea have bile acid diarrhoea.
3-5
Based on the pathophysiology, bile acid diarrhoea is classified into: type 1 caused by ileal resection, disease or injury, type 2 is idiopathic or primary, and type 3 is secondary to other conditions, e.g. cholecystectomy, where the terminal ileum appears normal.
2,6
Thus, bile acid diarrhoea can be caused by reduced bile acid uptake through injured or missing ileal enterocytes (type 1, could be termed "true malabsorption"). Type 2 and 3 bile acid diarrhoea are characterised by excessive amounts of bile acids entering a normal terminal ileum, thereby exceeding the absorptive capacity, either due to increased hepatic bile acid synthesis and/or defect regulation. Primary (type 2) bile acid diarrhoea is the result of a defect in the negative feedback whereby fibroblast growth factor-19 (FGF19), produced by ileal enterocytes as a response to excess bile acids in the terminal ileum via farnesoid X receptor (FXR), inhibits bile acid synthesis in hepatic cells. 7, 8 On average, FGF19 levels in patients with primary bile acid diarrhoea are reduced to approximately the half of healthy individuals. [8] [9] [10] Furthermore, the postprandial concentration of FGF19 is correlated with a low SeHCAT retention fraction.
11
75 Selenium homotaurocholic acid test (SeHCAT) is the gold standard for diagnosis of bile acid malabsorption because of its safety, relatively low cost, low radiation exposure, and very high specificity and sensitivity. 7, 12, 13 During the SeHCAT test, a capsule containing the radiolabelled 75 Se synthetic homocholic acid conjugated with taurine is ingested orally. The patient is scanned with a gammacounting camera 1 to 3 hours after administration and again 7 days later to measure the whole-body retention of SeHCAT. The result is given as a fraction of baseline. 
| Statistics
Questionnaires were collected and managed using the web-based application REDCap (Research Electronic Data Capture, Vanderbilt University, Nashville, Tennessee) hosted at Aarhus University. 19 REDCap is designed to support data capture. Descriptive statistics were performed on all baseline parameters stratified by type of bile acid diarrhoea and tested for differences. Numerical, nonparametric data were evaluated using Kruskal-Wallis tests and dichotomous data were evaluated using chi-square tests. Associations between patient characteristics and diarrhoea were explored by logistic regression analysis; Independent variables were 1) age, 2) gender, 3) time since diagnosis of bile acid diarrhoea 4) type of bile acid diarrhoea, and 5) retention fraction at SeHCAT. Dependent variables were 1) loose or liquid diarrhoea (Bristol stool scale 6-7), 2) bothersome diarrhoea, 3) frequency of bowel movements, and 4) change in diarrhoea since diagnosis of bile acid diarrhoea. For each model of logistic regression, step backward elimination was applied. Results are given as odds ratios (OR) with 95% confidence interval and P < 0.05 is considered statistically significant. All statistical analyses were performed using STATA version 13.0.
3 | RESULTS
| Patient cohort
Among 594 patients diagnosed with bile acid diarrhoea, 546 were alive in 2016. Three hundred and seventy-seven of these patients (69%) responded to the questionnaire (Table 1) . Among respondents, 121 had type 1 bile acid diarrhoea (due to ileal dysfunction, including Crohn's disease and/or resection), 198 patients had type 2 (idiopathic/primary), and 58 patients had type 3 bile acid diarrhoea (all after cholecystectomy) ( Table 1 ). Patients that suffered from both type 1 and 3 bile acid diarrhoea (n = 15) were classified as type 1. Further demographic information is given in Table 1 .
Based on retention fractions by SeHCAT, 254 patients (67%) had severe, 68 (18%) had moderate and 55 (15%) had mild bile acid malabsorption (Table 1 ). There was a statistically significant difference in SeHCAT retention fractions between the three groups of bile acid diarrhoea, with type 1 and type 3 having lower rates than type 2.
| Diarrhoea
Among the 377 respondents, 273 (74%) still reported bothersome diarrhoea and 129 (34%) had loose or liquid stools defined as Bristol stool scale of 6 or 7 (Table 2) . Data on stool consistency in each of the three types of bile acid diarrhoea are shown in Figure 1 . Number of bowel movements per day was three or less in 219 (59%), four to seven in 129 (35%), and more than seven in 24 (6%) patients (Table 2) .
Overall, 234 patients (62%) used some sort of anti-diarrhoeal medication at follow-up, and only 115 patients (34%) had had at least 1 month without use of medication since diagnosis (Table 2 ).
The used medications were colestyramine by 88 patients (38%), colesevelam by 74 (32%), colestipol by 10 (4%), loperamide by 72 (31%), and ispaghula husk by 51 (22%) (Figure 2 ). Among patients taking medication against bile acid diarrhoea, 157 (67%) used it on a daily basis, 31 (13%) used it two to three times per week, and 47 (20%) used it less than three times per week (Table 2) .
Since diagnosis by SeHCAT, and initiation of treatment, diarrhoea had improved in 184 patients (50%), were unaltered in 115 (31%), and were worsened in 69 (19%) ( Table 2 ).
| Self-assessed quality of life
Median visual analogue scale (VAS) score (0 best, 10 worst) was 4.2 for overall severity of diarrhoea, 3.8 for impact of diarrhoea on everyday life, 3.8 for concern about bowel disease, and 3.6 for impact of bile acid diarrhoea on general wellbeing. The percentage of respondents giving a VAS of at least 7 (severe) was 21% for overall severity of diarrhoea, 20% for impact on everyday life, 22% for concern about bowel disease and 17% for the impact of bile acid diarrhoea on general wellbeing.
| Associations between patient characteristics and diarrhoea
Lower retention fractions of the SeHCAT were associated with loose or liquid stools (OR 1.08 per 1% decrease in SeHCAT retention rate, 95% CI 1.02-1.12, P = 0.007). Furthermore, there was a trend towards an association between lower retention fractions of the T A B L E 1 Background information on patients diagnosed with bile acid diarrhoea defined by a 7-d retention fraction of SeHCAT below 15% 
| DISCUSSION
The main finding of this study was that the majority of patients with bile acid diarrhoea continued to have bothersome diarrhoea in spite of correct diagnosis by SeHCAT and appropriate initial treatment.
Two-thirds of patients reported continuous use of medication against bile acid diarrhoea. Therefore, it is surprising that only half of those diagnosed considered their diarrhoea better than before diagnosis and treatment.
To the best of our knowledge, this present study is by far the largest report on bile acid diarrhoea to date. The questionnaire response rate of 69% was acceptable and there was no significant difference in baseline characteristics among responders and nonresponders. Data are of general interest because it is estimated that 1% of the Western countries population suffers from bile acid diarrhoea. 8, 20, 21 Long-term follow-up studies of patients with bile acid diarrhoea are scarce, but most consider bile acid diarrhoea a chronic condition. 22, 23 This is supported by the data from our cohort with patients still having symptoms after a 13 years follow-up. In a previous study, Lin et al followed 58 patients with the diagnosis of bile acid diarrhoea confirmed by SeHCAT up to 11.6 years and found that 38% were still on bile acid sequestrants treatment, 28% used other treatments (e.g. loperamide) and 34% did not use any therapy, mainly because of poor tolerability. Patients that did not use medication had no significant improvement in bowel function, which strongly indicate that bile acid diarrhoea is a chronic condition. 23 Another study followed 16 of 33 patients, also diagnosed with bile acid diarrhoea by SeHCAT, up to 9.4 years after diagnosis, and found that symptoms were unchanged in 13 of 16 patients. A new
SeHCAT test made at follow-up demonstrated similarly low and almost identical values compared to the time of diagnosis, also confirming that bile acid diarrhoea is chronic. Patients that could accept colestyramine treatment had a significant reduction in the number of bowel movements, while the six of 13 patients who had discontinued treatment because of side effects all had recurrence of symptoms.
22
Despite its utility, safety and relatively low cost, SeHCAT is not available in many countries, and the chances that it will become routine globally seem poor. A pragmatic solution where no diagnostic test of bile acid malabsorption is available has been a trial of colestyramine. 14 This approach is convenient, since a positive response to colestyramine treatment is correlated with lower SeHCAT retention fractions. 4, 6, 21 Response to colestyramine has been demonstrated in 96% of patients with a SeHCAT retention fractions <5%, in 80% of patients with retention fraction <10%, and in 70% with retention fraction <15%. 4 Thus, lack of response to colestyramine treatment may lead The main limitation of our study is that all information on the use of medication was self-reported. Thus, some patients may have overestimated their adherence to treatment. We did not ask for exact dosage of bile acid sequestrant because we considered such information highly doubtful among patients who had started, and sometimes ended, treatment several years ago. Before SeHCAT, all patients had undergone standard evaluation for chronic diarrhoea to rule out chronic pancreatitis and coeliac disease. This also includes colonoscopy with multiple biopsies. Thus, none of the patients had microscopic colitis when the diagnosis of bile acid diarrhoea was made. Some may have developed this later, but we expect the proportion to be very small and without effect on the conclusions from the present paper.
The retrospective design of our study carries a substantial risk of recall bias. This is especially important because most patients were diagnosed several years before follow-up. For that reason and to achieve a high response rate, we kept the questionnaire very simple.
Our focus was on stool frequency, form, bothersome diarrhoea and quality of life. Most patients with bile acid diarrhoea have other symptoms, including urgency, bloating, flatulence, abdominal pain and abdominal gurgling. These symptoms were missed by our questionnaire and it is a limitation to the conclusions drawn. Future prospective studies should include consideration of diet intervention and evaluation of symptoms other than diarrhoea.
After a diagnosis of bile acid diarrhoea is confirmed by SeHCAT, patients are typically seen for 3-5 visits in our out-patient clinic. At these visits, patients are instructed in correct dosage and intake of bile acid sequestrants and the effect is evaluated. Start dosages of colestyramine and colesevalam are 1 gram two times daily and 625 two times daily, respectively. Usually, these are increased to no more than 4 gram two times daily and 1250 mg three times daily respectively. A diet with a low content of fat reduces bile acid diarrhoea.
Dietary advice is given by the physician at our unit, but strict instructions by a dietitian would potentially have a better effect.
| CONCLUSION
Despite diagnosis verified by SeHCAT and correct initial treatment, many patients diagnosed with bile acid malabsorption still suffer from bothersome diarrhoea and only half experience a relief in diarrhoea. This calls for long-term follow-up with adjustment of treatment and also for new treatment principles for bile acid diarrhoea.
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